

Unprecedented changes to the availability and structure of health funding, specifically from the USA, have had substantial impacts on research programmes, collaborations, and, most importantly, vulnerable populations in low-income and middle-income countries. For nearly three decades, South Africa has served as a crucial location for HIV and other infectious disease research, and in the process, produced internationally recognised experts in the field.1 Although South African health research, and similar programmes in low-income and middle-income countries, have benefitted substantially from international grant support, through deep and organic collaborations with US partners, the disruption in funding requires urgent rethinking to ensure the long-term sustainability of health research in South Africa and beyond.
HIV
|15th Jan, 2026
|The Lancet
HIV
|15th Jan, 2026
|The Lancet
HIV
|15th Jan, 2026
|The Lancet
HIV
|15th Jan, 2026
|The Lancet
HIV
|15th Jan, 2026
|The Lancet
HIV
|15th Jan, 2026
|The Lancet
HIV
|27th Nov, 2025
|The Lancet